CTTN and breast cancer: Mechanistically, CTTN downregulates DKK-1, a Wnt antagonist, in HER2+ breast cancer, resulting in activation of the Wnt signaling pathway and expansion of the number of CSCs, as well as resistance to trastuzumab (Figure 4E).